UPDATED RESULTS FROM THE PHASE 1 STUDY OF SONROTOCLAX (BGB-11417), A NOVEL BCL2 INHIBITOR, IN COMBINATION WITH ZANUBRUTINIB FOR RELAPSED/REFRACTORY CLL/SLL DEMONSTRATE DEEP AND DURABLE RESPONSES
EHA Library, Chan Y. Cheah,
4159236
A RANDOMIZED, MULTI-CENTER STUDY OF CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) WITH OR WITHOUT DARATUMUMAB (D) FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): THE ADVANCE CLINICAL TRIAL
EHA Library, C. Ola Landgren,
4159284
ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-KRD) FOR HIGH-RISK (HR) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): FIRST-TIME REPORT OF THE FULL COHORT OF TRANSPLANT-ELIGIBLE (TE) PATIENTS IN THE GMMG-CONCEPT TRIAL
EHA Library, Lisa Leypoldt,
4159286
DURABLE EFFICACY WITH FIXED-DURATION EPCORITAMAB + POLATUZUMAB VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) FOR 1L DIFFUSE LARGE B-CELL LYMPHOMA (EPCORE NHL-5)
EHA Library, Daniel Kerr,
4159324
LOW RATES OF HIGH-GRADE TOXICITIES WITH GLPG5101, A FRESH, STEM-LIKE, EARLY MEMORY PHENOTYPE ANTI-CD19 CAR T-CELL THERAPY IN PATIENTS WITH NON-HODGKIN LYMPHOMA IN THE ATALANTA-1 STUDY
EHA Library, Pim Mutsaers,
4159358
TREATMENT OF PATIENTS WITH SEVERE TRANSFUSION-DEPENDENT ß-THALASSEMIA WITH CS-101, AN AUTOLOGOUS, EX VIVO EDITED, CD34+ HEMATOPOIETIC STEM CELL PRODUCT USING INNOVATIVE TRANSFORMER BASE EDITOR (TBE)
EHA Library, Jia Chen,
4159368